条款清单显示,迈兰将出售其持有的印度Biocon公司价值最高达3.63亿美元的股份

路透中文
Jul 13
更新 1-条款清单显示,迈兰将出售其持有的印度Biocon公司价值最高达3.63亿美元的股份

在整份文档中补充了更多来自条款清单的详细信息

Yantoultra Ngui

路透新加坡7月13日 - 据路透看到的条款清单显示,全球医疗保健公司Viatris(VTRS.O)旗下的Mylan Inc计划出售印度制药商Biocon Ltd(BION.NS)最多9200万股股份,价值最高达348.1亿印度卢比(合3.63亿美元)。

  • 此次出售占Biocon已发行股份的5.64%。这是一笔二级市场出售,即股份由现有投资者出售,Biocon将不会获得这笔资金。

  • 最低报价为每股378.50卢比,较Biocon周一410.95卢比的收盘价折让7.9%。

  • 迈兰和Biocon均未立即回复通过电子邮件发出的置评请求。

  • 花旗全球市场印度公司和杰富瑞印度公司是此次交易的联合簿记管理人和经纪商。

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10